Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Selective activation of PI3Kalpha/Akt/GSK-3beta signalling and cardiac compensatory hypertrophy during recovery from heart failure.

Braz JC, Gill RM, Corbly AK, Jones BD, Jin N, Vlahos CJ, Wu Q, Shen W.

Eur J Heart Fail. 2009 Aug;11(8):739-48. doi: 10.1093/eurjhf/hfp094.

2.

Genetic ablation of IRAK4 kinase activity inhibits vascular lesion formation.

Rekhter M, Staschke K, Estridge T, Rutherford P, Jackson N, Gifford-Moore D, Foxworthy P, Reidy C, Huang XD, Kalbfleisch M, Hui K, Kuo MS, Gilmour R, Vlahos CJ.

Biochem Biophys Res Commun. 2008 Mar 14;367(3):642-8. doi: 10.1016/j.bbrc.2007.12.186. Epub 2008 Jan 9.

PMID:
18190779
3.

Solenopsin, the alkaloidal component of the fire ant (Solenopsis invicta), is a naturally occurring inhibitor of phosphatidylinositol-3-kinase signaling and angiogenesis.

Arbiser JL, Kau T, Konar M, Narra K, Ramchandran R, Summers SA, Vlahos CJ, Ye K, Perry BN, Matter W, Fischl A, Cook J, Silver PA, Bain J, Cohen P, Whitmire D, Furness S, Govindarajan B, Bowen JP.

Blood. 2007 Jan 15;109(2):560-5. Epub 2006 Sep 21.

4.

Synthesis of fluorescent derivatives of wortmannin and demethoxyviridin as probes for phosphatidylinositol 3-kinase.

Giner JL, Kehbein KA, Cook JA, Smith MC, Vlahos CJ, Badwey JA.

Bioorg Med Chem Lett. 2006 May 1;16(9):2518-21. Epub 2006 Feb 7.

PMID:
16464575
5.

Complete inhibition of anisomycin and UV radiation but not cytokine induced JNK and p38 activation by an aryl-substituted dihydropyrrolopyrazole quinoline and mixed lineage kinase 7 small interfering RNA.

Wang X, Mader MM, Toth JE, Yu X, Jin N, Campbell RM, Smallwood JK, Christe ME, Chatterjee A, Goodson T Jr, Vlahos CJ, Matter WF, Bloem LJ.

J Biol Chem. 2005 May 13;280(19):19298-305. Epub 2005 Feb 28.

6.

A cell-based immunocytochemical assay for monitoring kinase signaling pathways and drug efficacy.

Chen H, Kovar J, Sissons S, Cox K, Matter W, Chadwell F, Luan P, Vlahos CJ, Schutz-Geschwender A, Olive DM.

Anal Biochem. 2005 Mar 1;338(1):136-42.

PMID:
15707944
7.

An anti-inflammatory role for a phosphoinositide 3-kinase inhibitor LY294002 in a mouse asthma model.

Duan W, Aguinaldo Datiles AM, Leung BP, Vlahos CJ, Wong WS.

Int Immunopharmacol. 2005 Mar;5(3):495-502.

PMID:
15683846
8.

Inhibitors of cellular signaling targets: designs and limitations.

Vlahos CJ, Stancato LF.

Methods Mol Biol. 2004;273:87-102. Review. No abstract available.

PMID:
15308795
9.

Effect of drotrecogin alfa (activated) on human endothelial cell permeability and Rho kinase signaling.

Zeng W, Matter WF, Yan SB, Um SL, Vlahos CJ, Liu L.

Crit Care Med. 2004 May;32(5 Suppl):S302-8.

PMID:
15118535
10.

Phosphoinositide 3-kinase regulates excitation-contraction coupling in neonatal cardiomyocytes.

McDowell SA, McCall E, Matter WF, Estridge TB, Vlahos CJ.

Am J Physiol Heart Circ Physiol. 2004 Feb;286(2):H796-805. Epub 2003 Oct 16.

11.

Insulin-stimulated trafficking of ENaC in renal cells requires PI 3-kinase activity.

Blazer-Yost BL, Esterman MA, Vlahos CJ.

Am J Physiol Cell Physiol. 2003 Jun;284(6):C1645-53. Epub 2003 Feb 26.

12.

Kinases as therapeutic targets for heart failure.

Vlahos CJ, McDowell SA, Clerk A.

Nat Rev Drug Discov. 2003 Feb;2(2):99-113. Review. No abstract available.

PMID:
12563301
13.

Protein kinase C betaII activation induces angiotensin converting enzyme expression in neonatal rat cardiomyocytes.

Zhang Y, Bloem LJ, Yu L, Estridge TB, Iversen PW, McDonald CE, Schrementi JP, Wang X, Vlahos CJ, Wang J.

Cardiovasc Res. 2003 Jan;57(1):139-46.

PMID:
12504823
14.

Expression of connective tissue growth factor is increased in injured myocardium associated with protein kinase C beta2 activation and diabetes.

Way KJ, Isshiki K, Suzuma K, Yokota T, Zvagelsky D, Schoen FJ, Sandusky GE, Pechous PA, Vlahos CJ, Wakasaki H, King GL.

Diabetes. 2002 Sep;51(9):2709-18.

15.

Decreased cardiac expression of vascular endothelial growth factor and its receptors in insulin-resistant and diabetic States: a possible explanation for impaired collateral formation in cardiac tissue.

Chou E, Suzuma I, Way KJ, Opland D, Clermont AC, Naruse K, Suzuma K, Bowling NL, Vlahos CJ, Aiello LP, King GL.

Circulation. 2002 Jan 22;105(3):373-9.

PMID:
11804995
16.

Decreased p38 MAPK activity in end-stage failing human myocardium: p38 MAPK alpha is the predominant isoform expressed in human heart.

Lemke LE, Bloem LJ, Fouts R, Esterman M, Sandusky G, Vlahos CJ.

J Mol Cell Cardiol. 2001 Aug;33(8):1527-40.

PMID:
11448140
17.

Signaling pathways mediated by the beta(2)-adrenergic receptor in the fibroblast: a novel role for PI 3-kinase.

Vlahos CJ.

J Mol Cell Cardiol. 2001 Jun;33(6):1049-51. No abstract available.

PMID:
11444912
18.

Role of PRL-3, a human muscle-specific tyrosine phosphatase, in angiotensin-II signaling.

Matter WF, Estridge T, Zhang C, Belagaje R, Stancato L, Dixon J, Johnson B, Bloem L, Pickard T, Donaghue M, Acton S, Jeyaseelan R, Kadambi V, Vlahos CJ.

Biochem Biophys Res Commun. 2001 May 25;283(5):1061-8.

PMID:
11355880
19.

Protein kinase C-alpha and -epsilon modulate connexin-43 phosphorylation in human heart.

Bowling N, Huang X, Sandusky GE, Fouts RL, Mintze K, Esterman M, Allen PD, Maddi R, McCall E, Vlahos CJ.

J Mol Cell Cardiol. 2001 Apr;33(4):789-98.

PMID:
11273731
20.

Ceramide induces the dephosphorylation and inhibition of constitutively activated Akt in PTEN negative U87mg cells.

Zinda MJ, Vlahos CJ, Lai MT.

Biochem Biophys Res Commun. 2001 Feb 2;280(4):1107-15.

PMID:
11162641
21.

LY-294002-inhibitable PI 3-kinase and regulation of baseline rates of Na(+) transport in A6 epithelia.

Păunescu TG, Blazer-Yost BL, Vlahos CJ, Helman SI.

Am J Physiol Cell Physiol. 2000 Jul;279(1):C236-47.

22.

Phosphoinositide 3-kinase is required for aldosterone-regulated sodium reabsorption.

Blazer-Yost BL, Păunescu TG, Helman SI, Lee KD, Vlahos CJ.

Am J Physiol. 1999 Sep;277(3):C531-6. doi: 10.1152/ajpcell.1999.277.3.C531.

PMID:
10484339
23.

Increased protein kinase C activity and expression of Ca2+-sensitive isoforms in the failing human heart.

Bowling N, Walsh RA, Song G, Estridge T, Sandusky GE, Fouts RL, Mintze K, Pickard T, Roden R, Bristow MR, Sabbah HN, Mizrahi JL, Gromo G, King GL, Vlahos CJ.

Circulation. 1999 Jan 26;99(3):384-91.

PMID:
9918525
24.

Insulin and insulin-like growth factor-I receptor mediated differentiation of 3T3-F442A cells into adipocytes: effect of PI 3-kinase inhibition.

Christoffersen CT, Tornqvist H, Vlahos CJ, Bucchini D, Jami J, De Meyts P, Joshi RL.

Biochem Biophys Res Commun. 1998 May 19;246(2):426-30.

PMID:
9610377
25.

Possible involvement of phosphatidylinositol 3-kinase in regulated exocytosis: studies in chromaffin cells with inhibitor LY294002.

Chasserot-Golaz S, Hubert P, Thiersé D, Dirrig S, Vlahos CJ, Aunis D, Bader MF.

J Neurochem. 1998 Jun;70(6):2347-56.

26.

Phosphatidylinositol 3-kinase activation is required for insulin-stimulated sodium transport in A6 cells.

Record RD, Froelich LL, Vlahos CJ, Blazer-Yost BL.

Am J Physiol. 1998 Apr;274(4):E611-7. doi: 10.1152/ajpendo.1998.274.4.E611.

PMID:
9575821
27.

Calmodulin activates phosphatidylinositol 3-kinase.

Joyal JL, Burks DJ, Pons S, Matter WF, Vlahos CJ, White MF, Sacks DB.

J Biol Chem. 1997 Nov 7;272(45):28183-6.

28.

Inhibition of neutrophil oxidative burst and granule secretion by wortmannin: potential role of MAP kinase and renaturable kinases.

Sue-A-Quan AK, Fialkow L, Vlahos CJ, Schelm JA, Grinstein S, Butler J, Downey GP.

J Cell Physiol. 1997 Jul;172(1):94-108.

PMID:
9207930
29.

Effects of prolonged ethinyl estradiol treatment on calcium channel binding and in vivo calcium-mediated hemodynamic responses in ovariectomized rats.

Bowling N, Bloomquist WE, Cohen ML, Bryant HU, Cole HW, Magee DE, Rowley ER, Vlahos CJ.

J Pharmacol Exp Ther. 1997 Apr;281(1):218-25.

PMID:
9103500
30.

Inhibition of MG-63 cell proliferation and PDGF-stimulated cellular processes by inhibitors of phosphatidylinositol 3-kinase.

Thomas JE, Venugopalan M, Galvin R, Wang Y, Bokoch GM, Vlahos CJ.

J Cell Biochem. 1997 Feb;64(2):182-95.

PMID:
9027579
31.

Synthesis and in vitro evaluation of new wortmannin esters: potent inhibitors of phosphatidylinositol 3-kinase.

Creemer LC, Kirst HA, Vlahos CJ, Schultz RM.

J Med Chem. 1996 Dec 6;39(25):5021-4.

PMID:
8960564
32.

LY295427, a novel hypocholesterolemic agent, enhances [3H]25-hydroxycholesterol binding to liver cytosolic proteins.

Bowling N, Matter WF, Gadski RA, McClure DB, Schreyer T, Dawson PA, Vlahos CJ.

J Lipid Res. 1996 Dec;37(12):2586-98.

33.

Rac GTPase interacts specifically with phosphatidylinositol 3-kinase.

Bokoch GM, Vlahos CJ, Wang Y, Knaus UG, Traynor-Kaplan AE.

Biochem J. 1996 May 1;315 ( Pt 3):775-9.

34.

Effects of wortmannin analogs on bone in vitro and in vivo.

Sato M, Bryant HU, Dodge JA, Davis H, Matter WF, Vlahos CJ.

J Pharmacol Exp Ther. 1996 Apr;277(1):543-50.

PMID:
8613966
35.

Studies on the mechanism of phosphatidylinositol 3-kinase inhibition by wortmannin and related analogs.

Norman BH, Shih C, Toth JE, Ray JE, Dodge JA, Johnson DW, Rutherford PG, Schultz RM, Worzalla JF, Vlahos CJ.

J Med Chem. 1996 Mar 1;39(5):1106-11.

PMID:
8676346
36.

Wortmannin and LY294002 inhibit the insulin-induced down-regulation of IRS-1 in 3T3-L1 adipocytes.

Smith LK, Vlahos CJ, Reddy KK, Falck JR, Garner CW.

Mol Cell Endocrinol. 1995 Aug 30;113(1):73-81.

PMID:
8674815
37.

Antagonists of phosphatidylinositol 3-kinase block activation of several novel protein kinases in neutrophils.

Ding J, Vlahos CJ, Liu R, Brown RF, Badwey JA.

J Biol Chem. 1995 May 12;270(19):11684-91.

38.

Phosphoinositide 3-kinase inhibition spares actin assembly in activating platelets but reverses platelet aggregation.

Kovacsovics TJ, Bachelot C, Toker A, Vlahos CJ, Duckworth B, Cantley LC, Hartwig JH.

J Biol Chem. 1995 May 12;270(19):11358-66.

39.

Investigation of neutrophil signal transduction using a specific inhibitor of phosphatidylinositol 3-kinase.

Vlahos CJ, Matter WF, Brown RF, Traynor-Kaplan AE, Heyworth PG, Prossnitz ER, Ye RD, Marder P, Schelm JA, Rothfuss KJ, et al.

J Immunol. 1995 Mar 1;154(5):2413-22.

PMID:
7868907
40.

Activation of pp70/85 S6 kinases in interleukin-2-responsive lymphoid cells is mediated by phosphatidylinositol 3-kinase and inhibited by cyclic AMP.

Monfar M, Lemon KP, Grammer TC, Cheatham L, Chung J, Vlahos CJ, Blenis J.

Mol Cell Biol. 1995 Jan;15(1):326-37.

41.

Role of phosphatidylinositol-3-kinase in insulin receptor signaling: studies with inhibitor, LY294002.

Sanchez-Margálet V, Goldfine ID, Vlahos CJ, Sung CK.

Biochem Biophys Res Commun. 1994 Oct 28;204(2):446-52.

PMID:
7980500
42.
43.
45.

Platelet-derived growth factor induces proliferation of hyperplastic human prostatic stromal cells.

Vlahos CJ, Kriauciunas TD, Gleason PE, Jones JA, Eble JN, Salvas D, Falcone JF, Hirsch KS.

J Cell Biochem. 1993 Aug;52(4):404-13.

PMID:
7693727
46.

Platelet derived growth factor (PDGF), androgens and inflammation: possible etiologic factors in the development of prostatic hyperplasia.

Gleason PE, Jones JA, Regan JS, Salvas DB, Eble JN, Lamph WW, Vlahos CJ, Huang WL, Falcone JF, Hirsch KS.

J Urol. 1993 Jun;149(6):1586-92.

PMID:
7684794
48.

The inhibition of phosphatidylinositol 3-kinase by quercetin and analogs.

Matter WF, Brown RF, Vlahos CJ.

Biochem Biophys Res Commun. 1992 Jul 31;186(2):624-31.

PMID:
1323287
49.

Design and implementation of a particle concentration fluorescence method for the detection of HIV-1 protease inhibitors.

Manetta JV, Lai MH, Osborne HE, Dee A, Margolin N, Sportsman JR, Vlahos CJ, Yan SB, Heath WF.

Anal Biochem. 1992 Apr;202(1):10-5.

PMID:
1621970
50.

Supplemental Content

Loading ...
Support Center